At Superluminal, we focus on membrane receptors that play essential roles in human health and represent important drug targets. These receptors, particularly a group called GPCRs, are critical for cell communication and response. Despite their importance, many GPCRs remain unexplored as drug targets, and we often lack detailed structural information. We are using our integrated platform to develop custom-designed medicines targeting GPCRs, with an initial focus on therapeutic areas where there is a significant unmet need for effective oral treatments.
Our HyperloopTM Platform facilitates the identification, design, and optimization of new small molecule drugs targeting GPCRs and supports further drug development to bring therapeutics to patients in need.
The platform integrates tools, technologies, and expertise to streamline discovery and validation efficiently by supporting biologists, chemists, computer scientists, and other R&D staff in their daily work.
Create an ensemble of conformations for any GPCR via proprietary predictive methods to generate a dynamic model in a few days.
Problem
Solution
Hyperloop™ is an integrated suite of computational and experimental tools to enable rapid structure-based drug discovery of small-molecule medicines against challenging GPCR Targets.
Accurate ADME Prediction
Problem: Late-stage failure in drug development is frequently caused by unacceptable ADMET properties.
Solution: We are developing AI/ML ADMET prediction tools to enable earlier more accurate predictions using a combination of public, private, and proprietary data sources. This allows us to select the best candidates to advance.
GOAL: Elucidate dynamic GPCR-ligand-signal effector complexes, at scale, to unlock full potential of existing validated GPCR targets, as well as novel GPCR targets.
There’s a huge opening to target GPCR conformation-induced ligand bias, heteromerization, and tissue-specific signaling cascades, creating best-in-class medicines. We are exploring a new frontier in drug discovery by targeting the unique ways that GPCRs interact with drug molecules. Designing drugs that activate specific signaling pathways within the cell leads to more precise and targeted effects. Understanding how different GPCRs combine to form complexes enables the discovery of drugs that modulate these interactions. Understanding tissue-specificity allows for the development of targeted drugs that maximize therapeutic benefit while minimizing side effects.
Partner with us to accelerate your drug discovery efforts and achieve breakthroughs with unprecedented speed and accuracy. Our unique cutting-edge technologies in generative biology, chemistry, and machine learning overcome the limitations of traditional approaches, leading to faster and more efficient development of new medicines.
Published September 2022 in Journal of Chemical Information and Modeling
Published March 2023 in Journal of Chemical Information and Modeling
Published August 2025 in Communications Chemistry